Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Dioxins | 13 | 2022 | 17 | 2.290 |
Why?
|
Puberty | 17 | 2022 | 58 | 2.270 |
Why?
|
Sexual Maturation | 10 | 2019 | 50 | 2.140 |
Why?
|
Environmental Pollutants | 13 | 2022 | 91 | 1.980 |
Why?
|
Environmental Exposure | 18 | 2022 | 209 | 1.840 |
Why?
|
Polychlorinated Biphenyls | 11 | 2022 | 39 | 1.720 |
Why?
|
Leydig Cells | 5 | 2012 | 11 | 1.490 |
Why?
|
Endocrine Disruptors | 5 | 2018 | 73 | 1.250 |
Why?
|
Child | 43 | 2023 | 4187 | 1.180 |
Why?
|
Hydrocarbons, Chlorinated | 7 | 2020 | 11 | 1.180 |
Why?
|
Pesticides | 8 | 2020 | 55 | 1.150 |
Why?
|
Testicular Hormones | 5 | 2004 | 10 | 1.090 |
Why?
|
Diabetes Mellitus, Type 1 | 6 | 2015 | 605 | 1.040 |
Why?
|
Glycoproteins | 5 | 2004 | 186 | 0.980 |
Why?
|
Body Height | 6 | 2017 | 68 | 0.970 |
Why?
|
Down Syndrome | 3 | 2023 | 47 | 0.970 |
Why?
|
Lead | 9 | 2022 | 41 | 0.960 |
Why?
|
Russia | 26 | 2022 | 53 | 0.940 |
Why?
|
Hypothyroidism | 2 | 2023 | 39 | 0.880 |
Why?
|
Congenital Hypothyroidism | 1 | 2023 | 13 | 0.840 |
Why?
|
Thyroid Diseases | 1 | 2023 | 26 | 0.830 |
Why?
|
Body Composition | 2 | 2019 | 146 | 0.780 |
Why?
|
Vitamin D | 3 | 2013 | 131 | 0.780 |
Why?
|
Male | 57 | 2024 | 27742 | 0.730 |
Why?
|
Adolescent | 29 | 2024 | 5835 | 0.720 |
Why?
|
Growth | 4 | 2010 | 22 | 0.640 |
Why?
|
Anti-Mullerian Hormone | 6 | 2012 | 62 | 0.640 |
Why?
|
Human Growth Hormone | 2 | 2011 | 17 | 0.620 |
Why?
|
Insulin Resistance | 2 | 2014 | 392 | 0.620 |
Why?
|
Semen | 4 | 2024 | 42 | 0.590 |
Why?
|
Testis | 5 | 2012 | 135 | 0.590 |
Why?
|
Obesity | 3 | 2015 | 1166 | 0.560 |
Why?
|
Growth Disorders | 3 | 2008 | 28 | 0.540 |
Why?
|
Polychlorinated Dibenzodioxins | 4 | 2022 | 10 | 0.540 |
Why?
|
Luteinizing Hormone | 4 | 2022 | 98 | 0.530 |
Why?
|
Cell Differentiation | 3 | 2012 | 1304 | 0.520 |
Why?
|
Blood Glucose | 3 | 2015 | 461 | 0.520 |
Why?
|
Prospective Studies | 15 | 2024 | 3067 | 0.500 |
Why?
|
Humans | 59 | 2024 | 59366 | 0.500 |
Why?
|
Receptors, Transforming Growth Factor beta | 2 | 2012 | 29 | 0.480 |
Why?
|
Receptors, Peptide | 2 | 2012 | 31 | 0.470 |
Why?
|
Metformin | 1 | 2015 | 64 | 0.460 |
Why?
|
Weight Gain | 3 | 2015 | 163 | 0.450 |
Why?
|
Endosulfan | 1 | 2013 | 2 | 0.430 |
Why?
|
Biomarkers | 4 | 2014 | 1306 | 0.430 |
Why?
|
Endocrine System | 1 | 2013 | 17 | 0.420 |
Why?
|
Cryptorchidism | 2 | 2003 | 8 | 0.420 |
Why?
|
Metabolic Syndrome | 1 | 2014 | 131 | 0.420 |
Why?
|
Androgens | 2 | 2010 | 47 | 0.410 |
Why?
|
Growth Inhibitors | 2 | 2003 | 25 | 0.410 |
Why?
|
Bone Morphogenetic Protein Receptors, Type I | 1 | 2012 | 5 | 0.410 |
Why?
|
Phthalic Acids | 2 | 2022 | 36 | 0.380 |
Why?
|
Hormones | 2 | 2009 | 60 | 0.380 |
Why?
|
Semen Analysis | 4 | 2024 | 20 | 0.370 |
Why?
|
Vitamin D Deficiency | 1 | 2012 | 41 | 0.370 |
Why?
|
Patient Simulation | 1 | 2012 | 67 | 0.370 |
Why?
|
Computer-Assisted Instruction | 1 | 2012 | 77 | 0.370 |
Why?
|
Parenting | 2 | 2014 | 67 | 0.370 |
Why?
|
Growth Hormone-Releasing Hormone | 1 | 2011 | 5 | 0.360 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 1 | 2011 | 11 | 0.360 |
Why?
|
Dwarfism | 1 | 2011 | 12 | 0.360 |
Why?
|
Parents | 2 | 2013 | 367 | 0.350 |
Why?
|
Liver Diseases | 1 | 2012 | 137 | 0.350 |
Why?
|
Vitamins | 1 | 2011 | 74 | 0.340 |
Why?
|
Mentors | 1 | 2011 | 116 | 0.330 |
Why?
|
Female | 22 | 2018 | 30719 | 0.330 |
Why?
|
Pseudohypoparathyroidism | 1 | 2009 | 1 | 0.330 |
Why?
|
Counseling | 1 | 2012 | 350 | 0.320 |
Why?
|
Thyroxine | 3 | 2023 | 52 | 0.320 |
Why?
|
Hormone Antagonists | 1 | 2009 | 12 | 0.320 |
Why?
|
Furans | 5 | 2021 | 33 | 0.320 |
Why?
|
Psychotic Disorders | 1 | 2011 | 149 | 0.320 |
Why?
|
Social Support | 2 | 2014 | 355 | 0.320 |
Why?
|
Insulin | 4 | 2015 | 673 | 0.300 |
Why?
|
Infant | 6 | 2023 | 1491 | 0.290 |
Why?
|
Antipsychotic Agents | 1 | 2011 | 292 | 0.290 |
Why?
|
Young Adult | 13 | 2024 | 4273 | 0.290 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2014 | 725 | 0.290 |
Why?
|
Fetus | 1 | 2007 | 93 | 0.280 |
Why?
|
Infant, Newborn | 5 | 2023 | 1283 | 0.280 |
Why?
|
Cohort Studies | 9 | 2022 | 2375 | 0.270 |
Why?
|
Diabetes Mellitus | 1 | 2012 | 515 | 0.270 |
Why?
|
Hexachlorobenzene | 3 | 2015 | 3 | 0.270 |
Why?
|
Dichlorodiphenyl Dichloroethylene | 3 | 2015 | 4 | 0.270 |
Why?
|
Virilism | 2 | 2003 | 4 | 0.270 |
Why?
|
Longitudinal Studies | 7 | 2019 | 1189 | 0.270 |
Why?
|
Testosterone | 4 | 2012 | 112 | 0.250 |
Why?
|
Thyroid Function Tests | 2 | 2023 | 13 | 0.250 |
Why?
|
Cardiovascular Diseases | 1 | 2013 | 788 | 0.240 |
Why?
|
RNA, Small Untranslated | 1 | 2024 | 18 | 0.230 |
Why?
|
Thyrotropin | 2 | 2023 | 34 | 0.220 |
Why?
|
Disorders of Sex Development | 1 | 2003 | 11 | 0.220 |
Why?
|
Proteome | 1 | 2024 | 141 | 0.210 |
Why?
|
Body Mass Index | 6 | 2019 | 831 | 0.210 |
Why?
|
Triptorelin Pamoate | 1 | 2003 | 1 | 0.210 |
Why?
|
Animals | 11 | 2018 | 19649 | 0.210 |
Why?
|
Penis | 1 | 2002 | 21 | 0.200 |
Why?
|
Diethylhexyl Phthalate | 1 | 2022 | 4 | 0.200 |
Why?
|
Protein-Arginine N-Methyltransferases | 2 | 2022 | 35 | 0.190 |
Why?
|
Hypoglycemia | 2 | 2013 | 66 | 0.190 |
Why?
|
Child, Preschool | 6 | 2012 | 1792 | 0.190 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2022 | 188 | 0.180 |
Why?
|
Enzyme Inhibitors | 1 | 2003 | 347 | 0.180 |
Why?
|
Pilot Projects | 4 | 2013 | 914 | 0.180 |
Why?
|
Spermatozoa | 2 | 2024 | 253 | 0.170 |
Why?
|
Patient Education as Topic | 2 | 2014 | 453 | 0.170 |
Why?
|
Electric Impedance | 1 | 2019 | 35 | 0.160 |
Why?
|
Reference Values | 3 | 2006 | 326 | 0.160 |
Why?
|
Feasibility Studies | 2 | 2012 | 525 | 0.160 |
Why?
|
Adult | 11 | 2022 | 15679 | 0.160 |
Why?
|
Insulin Infusion Systems | 2 | 2013 | 10 | 0.160 |
Why?
|
Steroid 17-alpha-Hydroxylase | 2 | 2012 | 4 | 0.160 |
Why?
|
Linear Models | 4 | 2013 | 403 | 0.160 |
Why?
|
Cross-Sectional Studies | 6 | 2019 | 2380 | 0.150 |
Why?
|
Cell Count | 2 | 2012 | 127 | 0.150 |
Why?
|
Organelle Biogenesis | 1 | 2018 | 15 | 0.150 |
Why?
|
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2018 | 30 | 0.150 |
Why?
|
PPAR alpha | 1 | 2018 | 29 | 0.150 |
Why?
|
Phosphoproteins | 2 | 2012 | 211 | 0.140 |
Why?
|
Graves Disease | 1 | 2017 | 15 | 0.140 |
Why?
|
Celiac Disease | 1 | 2017 | 15 | 0.140 |
Why?
|
Age Factors | 5 | 2015 | 1504 | 0.140 |
Why?
|
Arginine | 2 | 2022 | 110 | 0.130 |
Why?
|
Gonadal Dysgenesis | 2 | 2008 | 3 | 0.130 |
Why?
|
Body Weight | 3 | 2017 | 368 | 0.130 |
Why?
|
DNA Methylation | 1 | 2018 | 271 | 0.130 |
Why?
|
Mice, Knockout | 3 | 2012 | 1997 | 0.120 |
Why?
|
Anthropometry | 3 | 2019 | 78 | 0.120 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2015 | 75 | 0.120 |
Why?
|
Mitochondria | 1 | 2018 | 343 | 0.120 |
Why?
|
Mice | 5 | 2018 | 10294 | 0.120 |
Why?
|
Time Factors | 3 | 2018 | 3615 | 0.110 |
Why?
|
Benzofurans | 2 | 2011 | 10 | 0.110 |
Why?
|
Leptin | 1 | 2014 | 83 | 0.110 |
Why?
|
Diet, Diabetic | 1 | 2014 | 13 | 0.110 |
Why?
|
Organ Size | 2 | 2004 | 164 | 0.110 |
Why?
|
Directive Counseling | 1 | 2014 | 38 | 0.110 |
Why?
|
Blood Glucose Self-Monitoring | 1 | 2014 | 59 | 0.110 |
Why?
|
Liver | 1 | 2018 | 795 | 0.110 |
Why?
|
Double-Blind Method | 1 | 2015 | 715 | 0.110 |
Why?
|
Rats | 2 | 2010 | 1910 | 0.110 |
Why?
|
Regression Analysis | 1 | 2014 | 486 | 0.110 |
Why?
|
Cholesterol | 1 | 2014 | 252 | 0.100 |
Why?
|
Triglycerides | 1 | 2014 | 231 | 0.100 |
Why?
|
Postpartum Period | 1 | 2015 | 187 | 0.100 |
Why?
|
Androstenedione | 1 | 2012 | 8 | 0.100 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2013 | 84 | 0.100 |
Why?
|
Immunoassay | 1 | 2013 | 67 | 0.100 |
Why?
|
Activin Receptors, Type I | 1 | 2012 | 14 | 0.100 |
Why?
|
Hyperglycemia | 1 | 2013 | 98 | 0.100 |
Why?
|
Androgen Antagonists | 2 | 2022 | 20 | 0.100 |
Why?
|
Reproductive Health | 1 | 2012 | 24 | 0.100 |
Why?
|
Adolescent Behavior | 1 | 2014 | 185 | 0.100 |
Why?
|
Neoplasms | 1 | 2022 | 1231 | 0.100 |
Why?
|
RNA, Messenger | 2 | 2010 | 1465 | 0.100 |
Why?
|
Self Care | 1 | 2014 | 207 | 0.100 |
Why?
|
Alanine Transaminase | 1 | 2012 | 38 | 0.100 |
Why?
|
Tandem Mass Spectrometry | 2 | 2022 | 141 | 0.090 |
Why?
|
Retrospective Studies | 1 | 2023 | 6069 | 0.090 |
Why?
|
Down-Regulation | 1 | 2012 | 305 | 0.090 |
Why?
|
Child Development | 1 | 2011 | 80 | 0.090 |
Why?
|
Qualitative Research | 2 | 2014 | 619 | 0.090 |
Why?
|
Stimulation, Chemical | 1 | 2010 | 18 | 0.090 |
Why?
|
Pregnancy Complications | 1 | 2015 | 364 | 0.090 |
Why?
|
Puberty, Delayed | 1 | 2010 | 3 | 0.090 |
Why?
|
Lead Poisoning | 1 | 2010 | 10 | 0.090 |
Why?
|
Steroids | 1 | 2010 | 52 | 0.080 |
Why?
|
Blotting, Northern | 1 | 2010 | 148 | 0.080 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2011 | 151 | 0.080 |
Why?
|
Pregnancy | 3 | 2015 | 2213 | 0.080 |
Why?
|
Cell Separation | 1 | 2010 | 145 | 0.080 |
Why?
|
Growth Hormone | 1 | 2009 | 17 | 0.080 |
Why?
|
Menarche | 1 | 2009 | 35 | 0.080 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 527 | 0.080 |
Why?
|
Age of Onset | 1 | 2009 | 170 | 0.080 |
Why?
|
Models, Animal | 1 | 2009 | 221 | 0.070 |
Why?
|
Immunohistochemistry | 1 | 2010 | 847 | 0.070 |
Why?
|
Dibenzofurans, Polychlorinated | 2 | 2022 | 2 | 0.070 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p19 | 1 | 2007 | 1 | 0.070 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2007 | 4 | 0.070 |
Why?
|
Gonadotrophs | 1 | 2007 | 5 | 0.070 |
Why?
|
Aging | 2 | 2010 | 710 | 0.070 |
Why?
|
Reproduction | 1 | 2007 | 89 | 0.070 |
Why?
|
Hypoglycemic Agents | 2 | 2013 | 192 | 0.070 |
Why?
|
Exercise | 1 | 2014 | 883 | 0.070 |
Why?
|
Mice, Transgenic | 1 | 2010 | 1206 | 0.070 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2007 | 152 | 0.070 |
Why?
|
Chemical Industry | 1 | 2005 | 8 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 1 | 2009 | 676 | 0.060 |
Why?
|
Proportional Hazards Models | 3 | 2011 | 674 | 0.060 |
Why?
|
Socioeconomic Factors | 3 | 2015 | 742 | 0.060 |
Why?
|
Multivariate Analysis | 3 | 2011 | 902 | 0.060 |
Why?
|
Practice Guidelines as Topic | 2 | 2006 | 705 | 0.060 |
Why?
|
Mice, Inbred C57BL | 2 | 2018 | 3231 | 0.060 |
Why?
|
Extracellular Vesicles | 1 | 2024 | 41 | 0.060 |
Why?
|
Mesylates | 1 | 2003 | 2 | 0.060 |
Why?
|
3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2003 | 2 | 0.060 |
Why?
|
Cholesterol Side-Chain Cleavage Enzyme | 1 | 2003 | 4 | 0.060 |
Why?
|
In Situ Nick-End Labeling | 1 | 2003 | 43 | 0.050 |
Why?
|
Phenotype | 2 | 2008 | 1137 | 0.050 |
Why?
|
Neonatal Screening | 1 | 2004 | 96 | 0.050 |
Why?
|
Population | 1 | 2003 | 14 | 0.050 |
Why?
|
Clitoris | 1 | 2003 | 5 | 0.050 |
Why?
|
Genitalia, Male | 1 | 2003 | 9 | 0.050 |
Why?
|
Karyotyping | 1 | 2003 | 44 | 0.050 |
Why?
|
Procarbazine | 1 | 2022 | 3 | 0.050 |
Why?
|
Diet | 3 | 2013 | 496 | 0.050 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2003 | 86 | 0.050 |
Why?
|
Gestational Age | 2 | 2015 | 178 | 0.050 |
Why?
|
Gonadotropins | 1 | 2002 | 14 | 0.050 |
Why?
|
Sertoli Cells | 1 | 2002 | 12 | 0.050 |
Why?
|
Dibutyl Phthalate | 1 | 2022 | 3 | 0.050 |
Why?
|
Bone Density | 1 | 2003 | 129 | 0.050 |
Why?
|
Sperm Count | 1 | 2022 | 15 | 0.050 |
Why?
|
Cell Division | 1 | 2003 | 443 | 0.050 |
Why?
|
Rats, Sprague-Dawley | 1 | 2003 | 574 | 0.050 |
Why?
|
Methylation | 1 | 2022 | 124 | 0.050 |
Why?
|
United States | 2 | 2015 | 7426 | 0.050 |
Why?
|
Sperm Motility | 1 | 2022 | 47 | 0.050 |
Why?
|
Chromatography, Liquid | 1 | 2022 | 126 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2003 | 1479 | 0.040 |
Why?
|
Surveys and Questionnaires | 3 | 2014 | 2516 | 0.040 |
Why?
|
Sex Factors | 1 | 2003 | 935 | 0.040 |
Why?
|
Demography | 2 | 2015 | 169 | 0.040 |
Why?
|
Cells, Cultured | 1 | 2004 | 2092 | 0.040 |
Why?
|
Absorptiometry, Photon | 1 | 2019 | 74 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2002 | 1027 | 0.040 |
Why?
|
Sensitivity and Specificity | 2 | 2011 | 1091 | 0.040 |
Why?
|
Mass Screening | 1 | 2004 | 648 | 0.040 |
Why?
|
Cell Line, Tumor | 1 | 2022 | 1368 | 0.040 |
Why?
|
Whole Genome Sequencing | 1 | 2018 | 63 | 0.040 |
Why?
|
Diet, Gluten-Free | 1 | 2017 | 6 | 0.040 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2017 | 16 | 0.040 |
Why?
|
Menstruation Disturbances | 1 | 2017 | 18 | 0.040 |
Why?
|
Dioxins and Dioxin-like Compounds | 1 | 2017 | 1 | 0.030 |
Why?
|
Environmental Monitoring | 1 | 2018 | 127 | 0.030 |
Why?
|
Diet, High-Fat | 1 | 2018 | 163 | 0.030 |
Why?
|
Adipose Tissue | 1 | 2019 | 283 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2013 | 805 | 0.030 |
Why?
|
Logistic Models | 2 | 2011 | 1235 | 0.030 |
Why?
|
Follow-Up Studies | 2 | 2011 | 2338 | 0.030 |
Why?
|
Psychology | 1 | 2015 | 44 | 0.030 |
Why?
|
Geography | 1 | 2013 | 32 | 0.030 |
Why?
|
Patient Medication Knowledge | 1 | 2013 | 3 | 0.030 |
Why?
|
Ketones | 1 | 2013 | 5 | 0.030 |
Why?
|
Parent-Child Relations | 1 | 2014 | 57 | 0.030 |
Why?
|
Spectrophotometry, Atomic | 1 | 2013 | 7 | 0.030 |
Why?
|
Milk | 1 | 2013 | 39 | 0.030 |
Why?
|
Luminescent Measurements | 1 | 2013 | 39 | 0.030 |
Why?
|
Luminescence | 1 | 2013 | 18 | 0.030 |
Why?
|
Self-Assessment | 1 | 2013 | 58 | 0.030 |
Why?
|
Receptors, Glucocorticoid | 1 | 2012 | 27 | 0.030 |
Why?
|
South Africa | 1 | 2012 | 10 | 0.030 |
Why?
|
Environmental Pollution | 1 | 2012 | 12 | 0.030 |
Why?
|
Estrogen Receptor alpha | 1 | 2012 | 45 | 0.030 |
Why?
|
Phytoestrogens | 1 | 2012 | 9 | 0.030 |
Why?
|
Risk Factors | 2 | 2015 | 4986 | 0.020 |
Why?
|
Focus Groups | 1 | 2014 | 288 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2014 | 210 | 0.020 |
Why?
|
Agriculture | 1 | 2012 | 30 | 0.020 |
Why?
|
Educational Status | 1 | 2013 | 264 | 0.020 |
Why?
|
Adaptation, Psychological | 1 | 2014 | 259 | 0.020 |
Why?
|
Research Design | 1 | 2015 | 555 | 0.020 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2011 | 41 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2018 | 1552 | 0.020 |
Why?
|
Breast Feeding | 1 | 2013 | 143 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2011 | 206 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2011 | 242 | 0.020 |
Why?
|
Rural Population | 1 | 2012 | 188 | 0.020 |
Why?
|
Body Size | 1 | 2010 | 23 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2012 | 439 | 0.020 |
Why?
|
Health Personnel | 1 | 2014 | 342 | 0.020 |
Why?
|
Health Behavior | 1 | 2013 | 452 | 0.020 |
Why?
|
Health Surveys | 1 | 2010 | 299 | 0.020 |
Why?
|
Genitalia | 1 | 2008 | 9 | 0.020 |
Why?
|
Genes, Recessive | 1 | 2008 | 49 | 0.020 |
Why?
|
Body Weights and Measures | 1 | 2008 | 33 | 0.020 |
Why?
|
Codon, Nonsense | 1 | 2008 | 51 | 0.020 |
Why?
|
Pedigree | 1 | 2008 | 183 | 0.020 |
Why?
|
Feeding Behavior | 1 | 2010 | 254 | 0.020 |
Why?
|
Signal Transduction | 1 | 2018 | 2903 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2008 | 188 | 0.020 |
Why?
|
Point Mutation | 1 | 2008 | 160 | 0.020 |
Why?
|
Pituitary Gland, Anterior | 1 | 2007 | 30 | 0.020 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2007 | 10 | 0.020 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2007 | 16 | 0.020 |
Why?
|
Massachusetts | 1 | 2013 | 2019 | 0.020 |
Why?
|
Dogs | 1 | 2008 | 314 | 0.020 |
Why?
|
Quality of Life | 1 | 2014 | 1137 | 0.020 |
Why?
|
Ribonucleoproteins | 1 | 2007 | 112 | 0.020 |
Why?
|
Base Sequence | 1 | 2008 | 1302 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2008 | 1553 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2008 | 1951 | 0.010 |
Why?
|
Infant Welfare | 1 | 2002 | 7 | 0.010 |
Why?
|
Diabetic Ketoacidosis | 1 | 2002 | 12 | 0.010 |
Why?
|
North Carolina | 1 | 2002 | 68 | 0.010 |
Why?
|
Child Welfare | 1 | 2002 | 52 | 0.010 |
Why?
|
Emergency Medical Services | 1 | 2002 | 255 | 0.010 |
Why?
|
Risk Assessment | 1 | 2005 | 1925 | 0.010 |
Why?
|
Physicians | 1 | 2002 | 440 | 0.010 |
Why?
|
Middle Aged | 1 | 2010 | 16310 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2002 | 5281 | 0.010 |
Why?
|